Until about 15 years ago, most men diagnosed with prostate cancer — no matter how aggressive — underwent surgery or radiation ...
Lantheus has inked a deal giving GE HealthCare the rights to carry its prostate cancer PET imaging agent in Japan, with the ...
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively ...
The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a ...
The R&B singer known for "This Is How We Do It" shared that follow up scans detected prostate cancer months after he ...
Live Science on MSN
Genetics: How do we inherit traits from our ancestors?
What makes every person unique? Part of the answer is in our genes.
HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company ...
GE HealthCare will develop, manufacture and commercialize Lantheus Holdings’ popular diagnostic agent for prostate cancer in ...
Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma Ltd. has secured an $8 million non-dilutive debenture financing from ...
15d
Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Discover Veracyte’s 2025 growth, innovative cancer diagnostics, and market strategy from Morgan Stanley’s Global Healthcare Conference.
The agreement includes the transfer of regulatory dossiers, manufacturing competencies and technical support to enable GE HealthCare to drive clinical development in Japan, towards potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback